Relmada Therapeutics (NASDAQ:RLMD) is a clinical-stage biotech company focused on developing novel therapies for the treatment of central nervous system (CNS) diseases, particularly those related to depression and other psychiatric disorders. Their portfolio includes multiple innovative projects aiming to address the unmet medical needs in mental health and pain management. One of their flagship products, REL-1017, is an NMDA receptor antagonist currently in advanced clinical trials for major depressive disorder, showcasing their commitment to pioneering treatments that can improve patient outcomes. With a clear objective to revolutionize the landscape of psychiatric and neurological care, Relmada Therapeutics is dedicated to advancing its research and development efforts to bring new, effective therapeutic options to market.